Image: cbx
Corresponding current findings will be discussed in the coming days (30 August to 2 September) at the annual congress of the German Society for Rheumatology (DGRh) in Leipzig. “Several international studies have recently dealt with the question of the extent to which patients at high risk of rheumatoid arthritis benefit from preventive drug treatment,” wrote the German specialist society. A promising drug is abatacept, which has a suppressing effect on the immune system. New studies show that early treatment with abatacept can reduce the occurrence of RA symptoms in people who already have symptoms and who have demonstrated inflammatory changes on magnetic resonance imaging.
Source: Nachrichten
